Followers | 507 |
Posts | 10138 |
Boards Moderated | 0 |
Alias Born | 04/28/2014 |
Wednesday, December 17, 2014 10:38:26 AM
bullish
$FGEN recent news/filings
## source: finance.yahoo.com
Tue, 09 Dec 2014 11:32:05 GMT ~ Coverage initiated on FibroGen by RBC Capital Mkts and Stifel
read full: http://finance.yahoo.com/q/ud?s=FGEN
*********************************************************
Fri, 21 Nov 2014 11:03:07 GMT ~ FIBROGEN INC Files SEC form 8-K, Material Modification to Rights of Security Holders, Amendments to Articles of Inc.
read full: http://biz.yahoo.com/e/141121/fgen8-k.html
*********************************************************
Wed, 19 Nov 2014 15:08:21 GMT ~ FibroGen, Inc. Announces Pricing of Its Initial Public Offering
[at noodls] - SAN FRANCISCO--(BUSINESS WIRE)--Nov. 13, 2014-- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics ...
read full: http://www.noodls.com/view/965FFCACE045817F9253B5797D6172A5BC567FBE
*********************************************************
Wed, 19 Nov 2014 15:08:04 GMT ~ FibroGen, Inc. Announces Full Exercise of Greenshoe Option
[at noodls] - SAN FRANCISCO--(BUSINESS WIRE)--Nov. 17, 2014-- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics ...
read full: http://www.noodls.com/view/DC458B462335AEB1E408CE3A9299E8EADCFB7907
*********************************************************
Mon, 17 Nov 2014 12:05:00 GMT ~ FibroGen, Inc. Announces Full Exercise of Greenshoe Option
[Business Wire] - FibroGen, Inc. , a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs, today announced that the underwriters of its initial public offering exercised in full their option to purchase an additional 1,215,000 shares of common stock from FibroGen at the initial public offering price of $18.00 per ...
read full: http://finance.yahoo.com/news/fibrogen-inc-announces-full-exercise-120500087.html
*********************************************************
$FGEN charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$FGEN company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/FGEN/company-info
Ticker: $FGEN
OTC Market Place: Not Available
CIK code: not found
Company name: FibroGen, Inc.
Incorporated In:
$FGEN share structure
## source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$FGEN extra dd links
Company name: FibroGen, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/FGEN/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/FGEN/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=FGEN+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=FGEN+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=FGEN+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/FGEN/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/FGEN/news - http://finance.yahoo.com/q/h?s=FGEN+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/FGEN/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/FGEN/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/FGEN/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/FGEN/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/FGEN/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/FGEN/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/FGEN/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/FGEN/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=FGEN+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/FGEN
DTCC (dtcc.com): http://search2.dtcc.com/?q=FibroGen%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=FibroGen%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=FibroGen%2C+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/FGEN/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/FGEN
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/FGEN/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/FGEN/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/FGEN/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/FGEN/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/FGEN/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/FGEN/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/FGEN/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=FGEN&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=FGEN
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/FGEN/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=FGEN+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=FGEN+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=FGEN
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=FGEN
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=FGEN+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/FGEN/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=FGEN+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/FGEN.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=FGEN
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/FGEN/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/FGEN/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/FGEN/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/FGEN/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/FGEN
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/FGEN
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/FGEN:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=FGEN
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=FGEN
$FGEN DD Notes ~ http://www.ddnotesmaker.com/FGEN
Recent FGEN News
- Traders Rush To Buy Biotech Following Q1 Earnings Beat • AllPennyStocks.com • 05/07/2024 03:55:00 PM
- FibroGen to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2024 08:10:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 08:05:13 PM
- FibroGen Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/06/2024 08:02:00 PM
- FibroGen to Report First Quarter 2024 Financial Results • GlobeNewswire Inc. • 04/29/2024 11:00:00 AM
- FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology A • GlobeNewswire Inc. • 04/24/2024 08:02:00 PM
- FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer • GlobeNewswire Inc. • 04/02/2024 09:46:47 PM
- FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/26/2024 11:00:00 AM
- FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer • GlobeNewswire Inc. • 03/11/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 12:19:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 12:18:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 12:17:01 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 09:08:13 PM
- FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 02/26/2024 09:06:00 PM
- FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea • GlobeNewswire Inc. • 02/26/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2024 01:33:43 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2024 01:29:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2024 01:28:24 AM
- FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 02/20/2024 12:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:37:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 01:08:37 AM
- FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024 • GlobeNewswire Inc. • 02/05/2024 12:00:00 PM
- FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer • GlobeNewswire Inc. • 01/25/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2023 12:28:47 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM